|
« Californians Injured on Florida Cruise Ships Subject to Short Deadlines for Making Their Claims |
Main
| Germany Halts Actos Sales for Bladder Cancer Risk »
|
 |
|
Actos Bladder Cancer Risk Brings France Ban
|
The French Health Products Safety Agency (AFSSAPS) has now banned the sale of the diabetes drug Actos in France because of an increased risk of bladder cancer. Although the ban became effective on July 11, 2011, the agency had given advance notice of the ban on June 6, 2011, so patients taking the drug could consult their physicians regarding alternative treatments.
The French agency took this action based on a study linking Actos use to increased incidents of bladder cancer. The study compared 155,000 patients in France taking the generic version of
Actos, with 1.3 million diabetics who were not using the drug. The study found that receiving a cumulative dose of 28,000 mg or more of
Actos resulted in an increased risk of bladder cancer.
Despite recognition of the link between Actos and bladder cancer,
Actos remains on the market in the United States. The U.S. Food and Drug Administration released a
safety announcement earlier this month regarding the link, but the FDA has not taken any substantive action to restrict the sale of
Actos in the U.S. or remove it from the market.
Patients in the U.S. concerned about the risk of bladder cancer from Actos should consult their physicians regarding alternative treatments. Other drugs containing
Actos include Actoplus Met, Actoplus Met XR and Duetact.
|
|
|
|
|
|
|
Posted By DeCarli Law on
July 22, 2011 10:44 am |
Permalink
|
|